Lazard Asset Management LLC Acquires New Holdings in UroGen Pharma Ltd. (NASDAQ:URGN)

Lazard Asset Management LLC bought a new position in UroGen Pharma Ltd. (NASDAQ:URGN) in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund bought 6,364 shares of the company’s stock, valued at approximately $67,000.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. JPMorgan Chase & Co. raised its position in shares of UroGen Pharma by 263.1% in the third quarter. JPMorgan Chase & Co. now owns 68,062 shares of the company’s stock valued at $864,000 after purchasing an additional 49,318 shares during the period. SG Americas Securities LLC grew its stake in UroGen Pharma by 44.1% in the 4th quarter. SG Americas Securities LLC now owns 20,269 shares of the company’s stock valued at $216,000 after buying an additional 6,207 shares during the last quarter. Rhumbline Advisers lifted its position in UroGen Pharma by 2.8% during the 4th quarter. Rhumbline Advisers now owns 51,270 shares of the company’s stock worth $546,000 after acquiring an additional 1,402 shares during the last quarter. Bank of New York Mellon Corp boosted its holdings in UroGen Pharma by 7.3% during the fourth quarter. Bank of New York Mellon Corp now owns 93,997 shares of the company’s stock valued at $1,001,000 after acquiring an additional 6,430 shares during the period. Finally, ARK Investment Management LLC boosted its holdings in UroGen Pharma by 15.2% during the fourth quarter. ARK Investment Management LLC now owns 140,148 shares of the company’s stock valued at $1,493,000 after acquiring an additional 18,514 shares during the period. 91.29% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

URGN has been the topic of a number of recent analyst reports. D. Boral Capital reiterated a “buy” rating and issued a $25.00 price objective on shares of UroGen Pharma in a research note on Thursday, May 8th. Guggenheim dropped their price target on UroGen Pharma from $40.00 to $15.00 and set a “buy” rating on the stock in a research report on Friday. HC Wainwright cut UroGen Pharma from a “buy” rating to a “neutral” rating in a research report on Thursday. LADENBURG THALM/SH SH initiated coverage on shares of UroGen Pharma in a research note on Wednesday, February 19th. They issued a “buy” rating and a $31.00 price objective on the stock. Finally, Scotiabank began coverage on shares of UroGen Pharma in a research note on Wednesday, April 16th. They set a “sector outperform” rating and a $23.00 target price for the company. Two equities research analysts have rated the stock with a hold rating, five have assigned a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $27.43.

UroGen Pharma Stock Up 2.7%

URGN opened at $4.19 on Monday. The company has a market capitalization of $193.19 million, a P/E ratio of -1.33 and a beta of 0.66. The company has a debt-to-equity ratio of 4.77, a current ratio of 9.00 and a quick ratio of 8.77. The firm’s fifty day moving average price is $10.03 and its two-hundred day moving average price is $10.65. UroGen Pharma Ltd. has a fifty-two week low of $3.42 and a fifty-two week high of $20.70.

UroGen Pharma (NASDAQ:URGN) last issued its earnings results on Monday, May 12th. The company reported ($0.92) earnings per share for the quarter, missing the consensus estimate of ($0.83) by ($0.09). The firm had revenue of $20.25 million for the quarter, compared to analyst estimates of $22.71 million. On average, analysts anticipate that UroGen Pharma Ltd. will post -3.12 EPS for the current year.

About UroGen Pharma

UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution.